Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the
first-line therapy for recurrent of metastatic nasophayngeal cancer